477 MD and [18F]FDG-PET/CT: complementing techniques or waste of valuable resources? 12 Figure 2. Study flowchart for MD on cytology and histopathology (n=130) AUS, atypia of undetermined significance; CHS, cancer hotspot panel for somatic mutation analysis; CNALOH, copy number alterations and loss of heterozygosity; [18F]FDG, 2-[18F]fluoro-2-deoxy-D-glucose; [18F]FDGPET/CT, positron emission tomography/computed tomography using [18F]FDG; FN, follicular neoplasm; MD, molecular diagnostics.1, oncocytic follicular neoplasm. a: cytological diagnosis on central review was FN. As the histopathological diagnosis was an oncocytic adenoma, full MD analysis was performed. b: Of the 42 patients with oncocytic cytology, five had partially unsuccessful MD based failed fusion analysis. As predefined, they were included in the statistical analysis as at least the somatic mutation analysis succeeded. c: in four patients with a driver mutation on CHS analysis (2 TERT, 1 PTEN, and 1 EGFR mutation), fusion analysis was performed to detect any additional driver mutations. d: concerned a HRAS mutation (VAF 0.33) that was not detected on CHS on cytology.
RkJQdWJsaXNoZXIy MTk4NDMw